Medtronic plc

MDT

NYSE

92.94

USD

+0.62(+0.67%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Medtronic plc fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

25.75

Price/Book

2.48

Debt/Equity

59.38%

Return on Equity

9.62%

Dividend Yield

3.02%

EBITDA

5.96B

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Statements Highlights

AnnualQuarterly

Period Ending	Apr 30, 2021	Apr 29, 2022	Apr 28, 2023	Apr 26, 2024	Apr 25, 2025
Total Revenue	30,117,000,000	31,686,000,000	31,227,000,000	32,364,000,000	33,537,000,000
Gross Profit	19,634,000,000	21,541,000,000	20,508,000,000	21,148,000,000	21,969,000,000
Operating Income	4,484,000,000	5,752,000,000	5,485,000,000	5,144,000,000	5,955,000,000
Net Income	3,606,000,000	5,039,000,000	3,758,000,000	3,676,000,000	4,662,000,000
Total Assets	93,083,000,000	90,981,000,000	90,948,000,000	89,981,000,000	—
Total Current Liabilities	8,509,000,000	12,394,000,000	9,051,000,000	10,789,000,000	—
Total Equity	51,602,000,000	52,722,000,000	51,665,000,000	50,420,000,000	—
Free Cash Flow	4,885,000,000	5,978,000,000	4,580,000,000	5,200,000,000	—
Cash from Operations	6,240,000,000	7,346,000,000	6,039,000,000	6,787,000,000	—
Cash from Investing	-2,866,000,000	-1,659,000,000	-3,493,000,000	-2,366,000,000	—
Cash from Financing	-4,136,000,000	-5,336,000,000	-4,960,000,000	-4,450,000,000	—
Net Change in Cash	-547,000,000	121,000,000	-2,171,000,000	-259,000,000	—

Medtronic plc

MDT

92.94

Medtronic plc fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations